Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.

Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J.

J Virol. 2010 Apr;84(7):3201-9. doi: 10.1128/JVI.02175-09. Epub 2010 Jan 13.

2.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

3.

Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.

Prabakaran M, Madhan S, Prabhu N, Geng GY, New R, Kwang J.

Antiviral Res. 2010 May;86(2):180-7. doi: 10.1016/j.antiviral.2010.02.315. Epub 2010 Feb 12.

PMID:
20153776
4.

Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.

Prabakaran M, Kolpe AB, He F, Kwang J.

Vaccine. 2013 Feb 27;31(10):1385-92. doi: 10.1016/j.vaccine.2013.01.003. Epub 2013 Jan 14.

PMID:
23328313
5.

Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages.

Prabakaran M, He F, Meng T, Madhan S, Yunrui T, Jia Q, Kwang J.

J Virol. 2010 Nov;84(22):11822-30. doi: 10.1128/JVI.00891-10. Epub 2010 Sep 15.

6.

Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.

Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T.

Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10.

PMID:
21911027
7.

Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.

Liu G, Song L, Reiserova L, Trivedi U, Li H, Liu X, Noah D, Hou F, Weaver B, Tussey L.

Vaccine. 2012 Nov 6;30(48):6833-8. doi: 10.1016/j.vaccine.2012.09.013. Epub 2012 Sep 18.

PMID:
23000130
8.

Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.

Prabakaran M, Meng T, He F, Yunrui T, Qiang J, Lin RT, Kwang J.

Clin Vaccine Immunol. 2011 Sep;18(9):1582-5. doi: 10.1128/CVI.05114-11. Epub 2011 Jul 13.

9.

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM.

PLoS One. 2008 Jan 30;3(1):e1501. doi: 10.1371/journal.pone.0001501.

10.

Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.

Tang XC, Lu HR, Ross TM.

Vaccine. 2010 Oct 4;28(42):6821-31. doi: 10.1016/j.vaccine.2010.08.040. Epub 2010 Aug 18.

PMID:
20727393
11.

Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models.

Song MS, Moon HJ, Kwon HI, Pascua PN, Lee JH, Baek YH, Woo GJ, Choi J, Lee S, Yoo H, Oh I, Yoon Y, Rho JB, Sung MH, Hong SP, Kim CJ, Choi YK.

J Microbiol. 2012 Jun;50(3):478-88. doi: 10.1007/s12275-012-1573-z. Epub 2012 Jun 30. Erratum in: J Microbiol. 2012 Aug;50(4):715. Woo, Kyu-Jin [corrected to Woo, Gyu-Jin].

PMID:
22752912
12.

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.

Vaccine. 2008 Oct 3;26(42):5393-9. doi: 10.1016/j.vaccine.2008.07.084. Epub 2008 Aug 14.

PMID:
18706956
13.

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.

Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM, Gambotto A.

J Virol. 2006 Feb;80(4):1959-64.

14.

Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Isakova-Sivak I, Chen LM, Bourgeois M, Matsuoka Y, Voeten JT, Heldens JG, van den Bosch H, Klimov A, Rudenko L, Cox NJ, Donis RO.

Clin Vaccine Immunol. 2014 May;21(5):722-31. doi: 10.1128/CVI.00819-13. Epub 2014 Mar 19.

15.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

16.

Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.

Wu Q, Xiao S, Fan H, Li Y, Xu J, Li Z, Lu W, Su X, Zou W, Jin M, Chen H, Fang L.

Antiviral Res. 2011 Dec;92(3):493-6. doi: 10.1016/j.antiviral.2011.10.001. Epub 2011 Oct 12.

PMID:
22020305
17.

Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.

Rajesh Kumar S, Syed Khader SM, Kiener TK, Szyporta M, Kwang J.

PLoS One. 2013 Jun 7;8(6):e63856. doi: 10.1371/journal.pone.0063856. Print 2013.

18.

Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.

Yang P, Duan Y, Zhang P, Li Z, Wang C, Dong M, Tang C, Xing L, Gu H, Zhao Z, Liu X, Zhang S, Wang X.

PLoS One. 2012;7(1):e30252. doi: 10.1371/journal.pone.0030252. Epub 2012 Jan 18.

19.

Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.

Yang P, Tang C, Luo D, Zhan Z, Xing L, Duan Y, Jia W, Peng D, Liu X, Wang X.

Vet Microbiol. 2010 Nov 20;146(1-2):17-23. doi: 10.1016/j.vetmic.2010.03.024. Epub 2010 Mar 31.

PMID:
20888151
20.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

Supplemental Content

Support Center